Clinical Trial Update: [18F]ACI-19626 PET in TDP-43 Proteinopathies [EARLY_Phase 1]

View source ↗

Summary

AC Immune is conducting an early Phase 1 study of the PET tracer [18F]ACI-19626 for imaging TDP-43 proteinopathies, including frontotemporal dementia, amyotroph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Amyotrophic Lateral Sclerosis
• Frontotemporal Dementia
• Limbic-predominant Age-related Tdp-43 Encephalopathy

Drugs mentioned

• [18F]ACI-19626

Snippet

Sponsor: AC Immune SA | Conditions: Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS) | EARLY_Phase 1 | Status: RECRUITING